Vor Biopharma Stock Rises 1.72% Amid Mixed Analyst Forecasts

On June 24, 2025, Vor Biopharma's stock price rose by 1.72% in pre-market trading, indicating a positive start to the day's trading session.

Analysts have provided mixed forecasts for Vor Biopharma. Some predict a significant decline in the stock price, while others suggest that the stock could find support at certain levels. The long-term average is seen as a potential buy signal if the stock breaks through it.

Recent analyst recommendations have varied. Wedbush downgraded Vor Biopharma from "Outperform" to "Neutral," adjusting the price target from $7.00 to $0.40. This change reflects a cautious outlook on the company's future performance.

Despite the mixed signals, Vor Biopharma's stock has shown resilience, with some analysts predicting a target price of $3.00. This optimism is based on the company's potential in the biopharma sector and its ongoing developments.